Inducing Immune Tolerance with Glycan-Containing NSAAs: In Vivo & In Vitro Assays to Validate Efficacy

Time: 2:15 pm
day: Conference Day Two


  • Understanding current approaches to treating autoimmune disease and attenuating immunogenicity of therapeutics broadly suppress the immune system
  • Tolerizing patients to specific antigens is a holy-grail challenge that can displace systemic immunosuppression
  • Illuminating the in vivo and in vitro assays used to validate efficacy for the immune tolerance approach
  • Highlighting GROBio’s ProGly approach to immunotolerization enables reversal of autoimmune disease and elimination of anti-drug antibodies without systemic immunosuppression